G1 Therapeutics Inc (NASDAQ:GTHX) has a beta value of 1.43 and has seen 0.46 million shares traded in the recent trading session. The GTHX stock price is -0.14% off its 52-week high price of $7.10 and 84.77% above the 52-week low of $1.08. If we look at the company’s 10-day average daily trading volume, we find that it stood at 5.79 million shares traded. The 3-month trading volume is 1.85 million shares.
The consensus among analysts is that G1 Therapeutics Inc (GTHX) is Buy stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 6 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.1.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
G1 Therapeutics Inc (NASDAQ:GTHX) trade information
Sporting -0.07% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the GTHX stock price touched $7.09 or saw a rise of 0.14%. Year-to-date, G1 Therapeutics Inc shares have moved 132.30%, while the 5-day performance has seen it change 66.71%. Over the past 30 days, the shares of G1 Therapeutics Inc (NASDAQ:GTHX) have changed 118.67%. Short interest in the company has seen 5.77 million shares shorted with days to cover at 6.22.
Wall Street analysts have a consensus price target for the stock at $4.5, which means that the shares’ value could drop -57.56% from the levels at last check today. The projected low price target is $3.0 while the price target rests at a high of $6.0. In that case, then, we find that the latest price level in today’s session is 15.37% off the targeted high while a plunge would see the stock lose 57.69% from the levels at last check today.
G1 Therapeutics Inc (GTHX) estimates and forecasts
Figures show that G1 Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 58.15% over the past 6 months, with this year growth rate of 53.76%, compared to 17.10% for the industry. Revenue growth from the last financial year stood is estimated to be -13.10%.
6 analysts offering their estimates for the company have set an average revenue estimate of 17.61M for the current quarter. 6 have an estimated revenue figure of 22.59M for the next ending quarter. Year-ago sales stood 12.3M and 14.87M respectively for this quarter and the next, and analysts expect sales will grow by 43.20% for the current quarter and -13.10% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 18.38% over the past 5 years.
G1 Therapeutics Inc (NASDAQ:GTHX)’s Major holders
Insiders own 10.93% of the company shares, while shares held by institutions stand at 37.09% with a share float percentage of 41.64%. Investors are also buoyed by the number of investors in a company, with G1 Therapeutics Inc having a total of 113.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 2.08 million shares worth more than $8.99 million. As of 2024-03-31, VANGUARD GROUP INC held 4.0236% of shares outstanding.
The other major institutional holder is SUSQUEHANNA INTERNATIONAL GROUP, LLP, with the holding of over 0.95 million shares as of 2024-03-31. The firm’s total holdings are worth over $4.11 million and represent 1.838% of shares outstanding.
